In March 2022, Medline (Ovid), Embase (Ovid), Scopus, and Web of Science were screened to identify eligible in vitro studies investigating the effects of antiresorptive and antiangiogenic compounds on orally derived cells.
Fifty-nine articles met the inclusion criteria. Bisphosphonates were used in 57 studies, denosumab in two, and sunitinib and bevacizumab in one. Zoledronate was the most commonly used nitrogen-containing bisphosphonate. The only non-nitrogen-containing bisphosphonate studied was clodronate. The most frequently tested tissues were gingival fibroblasts, oral keratinocytes, and alveolar osteoblasts. These drugs caused a decrease in cell proliferation, viability, and migration.
Antiresorptive and antiangiogenic drugs displayed cytotoxic effects in a dose and time-dependent manner. Additional research is required to further elucidate the pathways of MRONJ.
方法:2022年3月,Medline(Ovid),Embase(Ovid),Scopus,和WebofScience进行了筛选,以确定合格的体外研究,研究抗再吸收和抗血管生成化合物对口服来源的细胞的影响。
结果:59篇文章符合纳入标准。在57项研究中使用了双膦酸盐,Denosumab合二为一,舒尼替尼和贝伐单抗合二为一。唑来膦酸盐是最常用的含氮双膦酸盐。研究的唯一非含氮双膦酸盐是氯膦酸盐。最常测试的组织是牙龈成纤维细胞,口腔角质形成细胞,和肺泡成骨细胞。这些药物导致细胞增殖减少,生存能力,和移民。
结论:抗吸收和抗血管生成药物以剂量和时间依赖性方式显示出细胞毒性作用。需要进一步的研究来进一步阐明MRONJ的途径。